Alphabet Inc.'s (NASDAQ: GOOGGoogle Cloud introduced two new AI-powered tools that hold the potential to revolutionize the drug development process for biotech and pharmaceutical companies.

With the aim of expediting the discovery and advancement of new drugs, these tools, Target and Lead Identification Suite and Multiomics Suite, leverage artificial intelligence to streamline crucial stages of drug development.

By harnessing the power of AI, Google Cloud intends to significantly reduce the time and cost associated with bringing new drugs to market.

Google Cloud's Target and Lead Identification Suite

At the Bio-IT World Conference, Google Cloud unveiled the Target and Lead Identification Suite, designed to assist biotech and pharmaceutical companies in predicting and comprehending protein structures—an essential aspect …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.